Marty J Duvall was appointed as CEO in 2020.
Marty has extensive experience from executive leadership roles in drug development and commercialization within the global biotechnology and pharmaceutical industry, including a unique experience from the oncology and hematology sphere.
Prior to joining Oncopeptides Marty was Chief Executive Officer of Tocagen Inc. Previously he served as Executive Vice President, Chief Commercial Officer of ARIAD pharmaceuticals, and led the company’s transformation into a fully integrated, global biotechnology company. Marty has been Senior Vice President and General Manager, oncology, at Merck & Co., Inc. Earlier he was Senior Vice President, global marketing and commercial operations at Abraxis Bioscience, Inc. and Senior Vice President, commercial operations, for MGI Pharma. He has held several commercialization, marketing and sales roles in oncology at Sanofi.
Marty holds a MA in chemistry from Johns Hopkins University, an MBA from the University of Kansas, and a BS in chemistry from Muhlenberg College.
Holdings in Oncopeptides: 8,800 shares and 406,262 options**.
Other Current positions: Chairman of Oncopeptides, Inc.